The discovery of activating mutations in the epidermal growth factor receptor (EGFR) gene
and development of tyrosine kinase inhibitors (TKIs) of EGFR have achieved a paradigm …

Alkaloids, a category of natural products with ring structures and nitrogen atoms, include
most US Food and Drug Administration approved plant derived anti-cancer agents …

Background Lung cancer has become the most common cancer type and caused the most
cancer deaths. Lung adenocarcinoma (LUAD) is one of the major type of lung cancer. This …

Purpose: EGFR-tyrosine kinase inhibitor (TKI) is a standard first-line therapy for activated
EGFR-mutated non–small cell lung cancer (NSCLC). Treatment options for patients with …

EGFR tyrosine kinase inhibitors (TKIs) are standard therapy for EGFR-mutant non-small cell
lung cancer (NSCLC); however, these tumours eventually acquire chemoresistance. U3 …

Importance An end-to-end efficacy evaluation approach for identifying progression risk after
epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor (TKI) therapy in patients …

Lung adenocarcinoma (LUAD) is the most frequent histological subtype of non-small cell
lung cancer. Cyclin B1 (CCNB1) is the vital initiator and controller of mitosis. Studies have …

Background Lung adenocarcinoma (LUAD) is a major cause of cancer death. Therefore,
identifying potential prognostic risk factors is critical to improve the survival of patients with …

Summary EGFR T790M mutation causes resistance to the first-generation tyrosine kinase
inhibitors (TKIs) in patients with non-small cell lung cancer (NSCLC). However, the …

Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignant cancer with complex
genomic variations, and no targetable genomic lesions have been found yet. Super …